Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QBECO in moderate to severe Crohn's Disease
NCT01809275Phase 2Completed
- Sponsor
- Qu Biologics
- Start
- Mar 2013
- Primary completion
- Feb 2016
- Modality
- Split/Subunit Vaccines, Live Attenuated Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of QBECO SSI in Crohn's disease, sponsored by Qu Biologics. Started Mar 2013; status: completed.
02
Drugs
QBECO SSI
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01809275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01809275.